Introduction
============

Age-related macular degeneration (AMD) is one of the most common causes of irreversible, severe vision loss in the elderly population of Western societies, often having a significant effect on quality of life ([@b4-co-2-253]; [@b13-co-2-253]).

Neovascular AMD is characterized by choroidal neovascularization (CNV). The pathophysiology of neovascular AMD is complex and involves numerous processes. Vascular endothelial growth factor (VEGF) plays a key role in many of these processes ([@b1-co-2-253]). VEGF is a stimulator of the angiogenesis associated with CNV: it plays a fundamental role in the stimulation of cell proliferation of the endothelium, increases vascular permeability and has a chemotactic effect on macrophages. Yet VEGF also induces blood vessel growth and is necessary for the preservation of normal vessels and vascular function ([@b20-co-2-253]; [@b19-co-2-253]; [@b3-co-2-253]).

Pegaptanib sodium (Macugen^®^, \[OSI\] Eyetech Pharmaceuticals, Pfizer) was the first anti-VEGF agent licensed for the treatment of neovascular AMD. It is an oligonucleotide that functions as an aptamer (from the Latin "*aptus*", to match/fit; and the Greek "*meros*", part) and, similar to an antibody, specifically blocks the activity of the VEGF~165~ isoform that is largely responsible for the formation of the CNV associated with neovascular AMD ([@b11-co-2-253]).

The efficacy of pegaptanib sodium was investigated in the VEGF Inhibition Study In Ocular Neovascularization (VISION): 2 concurrent prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials ([@b10-co-2-253]). VISION defined broad inclusion parameters, including patients with all angiographic subtypes (predominant classic, minimally classic and occult lesions) and with visual acuity (VA) between 20/320 and 20/40. Patients were randomized to receive intravitreal (ITV) injections of pegaptanib sodium (0.3 mg, 1.0 mg, or 3.0 mg) or sham injection in 1 eye every 6 weeks over a period of 48 weeks. The study included all patients with classic and occult CNV, despite the fact that patients with predominantly classic lesions could have received additional photodynamic therapy (PDT) if it was considered appropriate by the investigator. The primary endpoint was the proportion of patients who had lost fewer than 15 letters (3 lines) of VA at 54 weeks and at years 2 and 3 (VA stabilization was defined as a loss of fewer than 15 letters over the duration of the trial).

VA stabilization was achieved in approximately 70% of patients administered pegaptanib sodium compared with 55% in the control group (p \< 0.001). VISION concluded that pegaptanib sodium was effective in all subtypes of neovascular AMD, including predominant classic, minimally classic, and occult lesion types. The treatment benefit was not only noted after 54 weeks, but also at all examinations carried out during years 1 and 2 of the study ([@b10-co-2-253]; [@b8-co-2-253]). During the second year, the therapeutic effect was maintained through administration of 6-weekly ITV injections ([@b8-co-2-253]).

In this review, we report the findings of our clinical experience with the agent over a period of 6 months at our clinic in Germany.

Material and methods
====================

The data reported were attained through clinical experience with compassionate use pegaptanib sodium in 50 eyes (of 49 patients) with progressive vision loss due to neovascular AMD, before and after the agent's approval in the European Union (EU).

At assessment, carried out up to a month prior to treatment initiation, patients were deemed eligible for treatment with pegaptanib sodium if they reported acute visual impairment or metamorphopsia and demonstrated occult or minimally classic CNV. Of the 50 eyes treated with pegaptanib sodium, 39 had occult CNV and 11 had minimally classic CNV. Most patients were female: 32 women compared with only 17 men, and had an average age of 78 years (age range of 54--87 years). Twenty-two of the patients had received previous treatment during the 3- to 6-month period prior to the first study injection. Of those 22 patients: 8 patients had received triamcinolone monotherapy; 1 had been treated with PDT monotherpay; 8 with PDT in combination with triamcinolone; 2 patients had received ITV injections of tissue plasminogen activator r-TPA and gas, and 3 had undergone cataract operations.

Baseline assessments included best-corrected VA (BCVA), slit lamp examination of the anterior segment, funduscopy, OCT, and measurement of IOP. The examinations were repeated at 4--6 weeks, at 3 months and at 6 months after the first injection. IOP and slit lamp examinations were also performed on days 1 and 2 post-injection. Fluorescein angiography (FA) of the ocular fundus was performed at baseline, post injection, at 3 months, and at 6 months. Baseline CRT and volume were assessed with OCT and compared with measurements taken at 1 month, at 3 months, and at 6 months post injection. All patients were monitored for a period of 6 months.

All patients received an ITV injection of pegaptanib sodium (0.3 mg). Indicators of the need for re-injection were increased intra-retinal fluid or a rise in CRT of more than 100 μm (measured by OCT), a decrease in VA or angiographically persisting leakage. An average of 2.74 injections were administered per patient; the majority of patients received 1 (15 patients) or 2 (17 patients) injections, but 8 patients received 3 injections, 5 received 4 injections, and 5 patients received 5 injections. The high percentage of patients that received only 1 or 2 injections during the 6-month follow up period of this study was a consequence of the need to apply for reimbursement for each separate injection at the outset of the study. As a result, a standardized injection regimen could not be established in some cases. Patients were deemed ineligible for treatment if they had maculopathy originating from a condition other than AMD, or if they exhibited signs of any acute ocular infection.

The ITV injection of pegaptanib sodium (0.3 mg) was performed in accordance with the guidelines for ITV injection published by the [@b18-co-2-253]. Before injection administration, the eye was washed with povidone iodide (5%) and the ciliae and lid regions were then wiped, also with povidone iodine (5%). The drape (as used for intraocular intervention) was applied, a speculum was inserted, and paracentesis was performed in all cases to reduce the intraocular volume. After dislocation of the conjunctivae (with the use of a sterile pad to avoid penetration of the conjunctiva and sclera at the same location), pegaptanib sodium (0.09 mL) was injected at a distance of 3.5 mm from the limbus. Antibiotic eye drops were then given.

Results
=======

The 6-month results from the 50 treated eyes were analyze retrospectively. Mean VA at baseline was 0.37 ± 0.24 and remained stable at 1 month and 3 months (0.37 ± 0.25). At 6 months, however, the mean BCVA had improved to 0.40 ± 0.26 (see [Figure 1](#f1-co-2-253){ref-type="fig"}).

VA measurements at 1 month post injection revealed that: 2 patients (4%) had lost 3 or more lines; 46 patients (92%) had stabilized (had lost or gained less than 3 lines); and 2 patients (4%) had gained more than 3 lines (see [Figure 2a](#f2a-co-2-253){ref-type="fig"}). VA measurements 3 months post injection demonstrated that: 1 patient (2%) had lost 3 or more lines; 48 patients (92%) had stabilized ±3 lines; and 1 patient (4%) had gained more than 3 lines (see [Figure 2b](#f2b-co-2-253){ref-type="fig"}). At final measurement, 6 months post injection: only 1 patient (2%) had lost more than 3 lines; 45 patients (90%) had stabilized within ±3 lines; and 4 patients (8%) had experienced an increase in VA of more than 3 lines (see [Figure 2c](#f2c-co-2-253){ref-type="fig"}).

Mean CRT, measured by OCT examination, at baseline was 251.19 ± 75.83 μm. Post-injection measurements or CRT recorded mean values of: 252.00 ± 71.27 μm at 1 month; 247.38 ± 66.28 μm at 3 months; and 251.63 ± 68.23 μm at 6 months (see [Figure 3](#f3-co-2-253){ref-type="fig"}).

Semi-quantitative evaluation of the angiographic images revealed stabilization or reduction in lesion size or exudation. During the 6-month period following first ITV administration of pegaptanib sodium, no conversion of occult CNV into a predominantly classic CNV was observed. One patient had an IOP of more than 21 mmHg when measured 1 month post-injection, but this returned to normal after management with topical anti-glaucoma therapy. No serious post-injection complications (eg, intraocular bleeding, retinal detachment, endophthalmitis, or cataract progression) were observed.

The following case study offers an illustration of the approach to treatment taken in the study.

Case study
----------

At baseline, Patient A complained of visual impairment and metamorphopsia in their better (left) eye. The right eye had a VA of approximately 0.03 and featured macular scarring due to neovascular AMD, and the left-eye had VA of 0.20 (see [Figure 4](#f4-co-2-253){ref-type="fig"}). VA measured after the first ITV injection of pegaptanib sodium was 0.40, which increased to 0.63 after 3 injections and stabilized at 0.60 after 5 injections. [Figure 5](#f5-co-2-253){ref-type="fig"} shows the angiographic findings after 5 injections with pegaptanib sodium (0.3 mg). After only the second injection Patient A reported that they were able to read and drive again.

Conclusion
==========

This paper is a report of our clinical experience with pegaptanib sodium for the treatment of neovascular AMD. As there were no approved therapies available for the treatment of occult and minimally classic CNV in 2005, patients who were administered pegaptanib sodium for treatment of neovascular AMD in September 2005 ahead of its EU licence did so through the compassionate use program ([@b18-co-2-253]). Eleven patients at our clinic were treated with pegaptanib sodium in advance of its licence being granted for the treatment of neovascular AMD in Germany in May 2006; 8 of those patients received more than 1 injection of the agent.

A total of 35 eyes were treated with multiple injections in the observation period. There was good clinical acceptance of the drug with no observation of severe side effects, such as endophthalmitis or retinal detachment. Re-treatment was also well tolerated among the patient group. One patient developed an elevation in their IOP after the first injection, but this was quickly and successfully managed with the use of topical anti-glaucoma medication. In total, patients were observed for a period of 6 months and some (4%--8%) benefited from an improvement in their vision of more than 3 lines. In comparison to the VISION trial there was a higher percentage of patients with stabilization of VA at the endpoint of our investigation (at month 6). No sub-analysis was performed to determine any possible relationship between lesion size and visual outcome. The OCT assessment of CRT at 1, 3, and 6 months post injection showed little change (see [Figure 3](#f3-co-2-253){ref-type="fig"}). No correlation was observed between CRT and VA.

During the period of observation, 5 patients switched therapy from selective anti-VEGF therapy with pegaptanib sodium to treatment with unselective anti-VEGF agents because of a lack of efficacy. No further visual impairment was observed in these patients. The efficacy of ranibizumab (Lucentis^®^, Genentech, Inc) for the treatment of neovascular AMD has been investigated in prospective, randomized, placebo-controlled multi-center studies: Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA), and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR). The data showed that BCVA stabilization was achieved in approximately 90% of patients (stabilization was defined as a loss of less than 3 lines on the Early Treatment Diabetic Retinopathy Study \[ETDRS\]) chart ([@b5-co-2-253]; [@b14-co-2-253], [@b15-co-2-253]). No such large-scale randomized clinical trials have been carried out to assess the efficacy of bevacizumab (Avastin^®^, Genentech, Inc) for ITV administration for neovascular AMD and the agent remains unlicensed for this indication at this time. However, the literature does report the findings of retrospective case control studies of up to 266 patients in which a decrease of CRT and an improvement of VA was reported in up to 38% of patients following treatment with ITV bevacizumab for neovascular AMD ([@b2-co-2-253]; [@b17-co-2-253]).

ITV anti-VEGF therapy requires periodic injections and, consequently, re-treatment tolerability is important. Our experience of pegaptanib sodium indicates that repetitive treatment is well tolerated by patients. At the time of writing, there are currently no consistent recommendations to advise on the exact pre-treatment diagnostic measures, follow-up examinations (eg, single OCT vs OCT plus angiography), or on the duration and frequency of follow-up assessments. In addition, it still remains unclear whether it is necessary to administer repeat injections every 6 weeks after initiation of a therapy for a 2-year period, or if clinical judgement can be used to determine whether the interval between successive injections can be prolonged. Two recent trials investigated a loading strategy for ranibizumab therapy -- the Prospective Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration (AMD) Treated with Intra-Ocular ranibizumab (PrONTO), and a Phase IIIb, multicenter, randomized, double-masked, sham Injection-controlled study of the Efficacy and safety of Ranibizumab in subjects with subfoveal CNV with or without classic CNV secondary to AMD (PIER). The approach involved the administration of 3 injections with subsequent re-treatment being administered as needed. The strategy appeared to result in superior treatment outcomes than those achieved when there are prolonged intervals between the re-treatment injections ([@b16-co-2-253]).

Pegaptanib sodium was the first anti-VEGF agent approved for ITV administration for neovascular AMD. The VA results of the VISION study are clearly inferior to those of the MARINA and ANCHOR studies with ranibizumab. At the time of writing, therefore, pegaptanib sodium is considered second-line therapy. However, VA efficacy is only one of the clinical considerations that must be taken into account. In our study, the safety profile of pegaptanib sodium during the observation period was good; no relevant systemic or ocular side effects were noted. Cardiovascular incidents and overall mortality in the pegaptanib sodium group were comparable to those of the sham injection group. In addition, a separate trial looking at ITV pegaptanib sodium injections over a 2-year period concluded that there was no clinical or angiographical-proven retinal or choroidal damage detectable ([@b10-co-2-253]). It should also be noted that there are currently no data concerning the safety of bevacizumab in the ocular environment. Systemic administration of the agent, as licensed for the treatment of colorectal cancer, has been noted to cause an elevation in the incidence of thrombembolic events, as well as gastrointestinal perforations ([@b21-co-2-253]).

The Safety Assessment of Intravitreal Lucentis fOR AMD (SAILOR) study investigated the safety profile of different dosages of ITV ranibizumab. After a follow-up period of 230 days, an elevated incidence of (cerebral) strokes was found in the study arm randomized to receive 0.5 mg ITV ranibizumab compared with those randomized to 0.3 mg ranibizumab. Patients with a history of apoplexy seemed to have a higher risk of apoplectic stroke. No difference was found for myocardial infarction or overall mortality ([@b6-co-2-253]). These data are of particular interest when considered in conjunction with animal studies that found ITV administration resulted in the substance being detectable systemically, indicating systemic bioavailability and a need to assume the possibility of associated side effects ([@b9-co-2-253]). This argument is further substantiated by reports in the literature of incidents where therapeutic effects were observed not only in the treatment eye, but also in the fellow eye ([@b12-co-2-253]).

The approval studies for pegaptanib sodium and ranibizumab clearly show that multiple injections are necessary over a prolonged period of time to maintain the effectiveness of therapy. It is also noteworthy that the implications of a permanent ocular or systemic blockade of all VEGF-A isoforms remain unclear at this time. In a clinical setting, therefore, it is critical to consider the potential systemic side effects of repeated treatments with nonselective VEGF inhibitors in those patients with a high cardiovascular risk profile or with a history of thromboembolic events.
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![Patient A: results of left-eye optical coherence tomography and late-phase angiography after 5 injections of pegaptanib sodium.](co-2-253f5){#f5-co-2-253}
